A Phase II Open Label Study of Sacituzumab Govitecan in Patients With Solid Tumor
The goal of this study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with solid tumor.
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
Solid Tumor
Gender
N/A
Date
October 2021 - December 2025
Study Type
Interventional
Study Phase
Phase 2
Product
Sacituzumab Govitecan-hziy
Beijing, China, 100006
Beijing, China, 100021
Beijing, China, 100142
Changchun, China, 130021
Fuzhou, China, 350014
Fuzhou, China, 350014
Guangzhou, China, 510655
Hangzhou, China, 310003
Hangzhou, China, 310022
Harbin, China, 150076
Hefei, China, 230001
Nanjing, China, 210029
Wuhan, China, 43006
Wuhan, China, 43006
Zhengzhou, China, 450000
Share Trial